Journal of Clinical and Experimental Toxicology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract - Journal of Clinical and Experimental Toxicology (2020) Volume 4, Issue 4

Study on the promiscuous nature and aggregation-tendency of 4- thiazolidinone derivatives

According to the International Diabetes Federation (IDF), type 2 diabetes mellitus as well as its complications caused the death of about 4.2 million adults in 2019. Long term hyperglycemic condition in diabetes leads to various complications causing degenerative diseases, which is normally occurs with age, under oxidative stress and due to non-enzymatic glycation of cellular protein. Diabetes mellitus is related with serious chronic complications like retinopathy, nephropathy, neuropathy and cardiovascular diseases.
Type 2 diabetes is a chronic disease. It is characterized by high levels of sugar in the blood. Type 2 diabetes is also called type 2 diabetes mellitus and adult-onset diabetes. That's because it used to start almost always in middle- and late-adulthood. However, more and more children and teens are developing this condition. Type 2 diabetes is much more common than type 1 diabetes, and is really a different disease. But it shares with type 1 diabetes high blood sugar levels, and the complications of high blood sugar.
Although many effective drugs are currently available, their diverse and often severe side effects require the development of new, safer alternative therapies2. The inhibition of aldose reductase (AR) enzyme can ease or even prevent the development of such long term complications of diabetes as kidney failure, blindness, or cardiovascular diseases. 4-thiazolidinone derivatives were designed as potential AR-inhibitors3; however, the promiscuous nature of these compounds must be investigated before applying them as drugs.  

  

Author(s): Kármen Szabó

Abstract Full Text PDF

Get the App